Hosseini Sayed Mohammad, Bakhtyari Elham Khosravi, Heshmat-Ghahdarijani Kiyan, Khalili Noushin
Department of Internal Medicine, Isfahan Endocrine and Metabolism Research Center, Isfahan, Iran.
Department of Cardiology, Isfahan University of Medical Sciences, Isfahan, Iran.
Adv Biomed Res. 2016 Nov 28;5:173. doi: 10.4103/2277-9175.194800. eCollection 2016.
Subclinical hyperthyroidism (SHy) is a widespread condition in which cardiovascular manifestations are frequently occur, but there is still a debate about the vascular responsiveness in it. Measuring flow-mediated dilation (FMD) and intimae-media thickness (IMT) are used to evaluate endothelial function in these patients.
Twenty-five patients with a diagnosis of exogenous SHy and 25 full matched healthy subjects were enrolled. At first FMD of brachial artery and IMT of common carotid artery were obtained from all the participants. In the second phase, in the second phase of study, the dosage of levothyroxine was reduced at least 25% of prior dosage, and this was continued until thyroid stimulating hormone became normal range. Measuring FMD and IMT was repeated after this intervention in the case group.
The mean age of case and control groups were 38.48 ± 12.05 and 36.72 ± 11.15 years, respectively. The mean of FMD in healthy people was dramatically higher than the subclinical hyperthyroid patients ( < 0.001) but no statistically significant difference was found for IMT ( = 0.459). After intervention in the case group, FMD was meaningfully increased ( < 0.001) but IMT of common carotid artery was not considerably changed ( = 0.491).
This study demonstrated that FMD decreased in exogenous subclinical hyperthyroid patients which could be partially restored by treatment. These findings suggest that treatment of subclinical hyperthyroid state could improve endothelial dysfunction and at the end decreased the cardiovascular complications.
亚临床甲状腺功能亢进(SHy)是一种普遍存在的疾病,常伴有心血管表现,但关于其血管反应性仍存在争议。测量血流介导的血管舒张功能(FMD)和内膜中层厚度(IMT)用于评估这些患者的内皮功能。
纳入25例诊断为外源性SHy的患者和25例完全匹配的健康受试者。首先,获取所有参与者肱动脉的FMD和颈总动脉的IMT。在研究的第二阶段,将左甲状腺素的剂量至少降低先前剂量的25%,并持续此操作直至促甲状腺激素恢复到正常范围。对病例组进行此干预后,重复测量FMD和IMT。
病例组和对照组的平均年龄分别为38.48±12.05岁和36.72±11.15岁。健康人的FMD平均值显著高于亚临床甲状腺功能亢进患者(<0.001),但IMT无统计学显著差异(=0.459)。病例组干预后,FMD显著增加(<0.001),但颈总动脉的IMT无明显变化(=0.491)。
本研究表明,外源性亚临床甲状腺功能亢进患者的FMD降低,治疗可使其部分恢复。这些发现提示,治疗亚临床甲状腺功能亢进状态可改善内皮功能障碍,最终降低心血管并发症。